Fox Chase Cancer Center | Strategic Alliance Partners

Novel strategies for patient education can help to build trust in and decrease the fear of lung cancer screening among patients.

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

Nivolumab/ipilimumab may offer superior overall survival to those with non–small cell lung cancer and solid tumor histology vs acinar histology.

Fox Chase Cancer Center has achieved Magnet designation for nursing excellence from the American Nurses Credentialing Center (ANCC) for the sixth consecutive time.

The COVID-19 pandemic has affected oncology practice in many ways. What will safe treating look like moving forward?

A real-world survival analysis showed that patients with metastatic RCC treated with axitinib plus pembrolizumab did not experience significantly improved survival outcomes compared with patients treated with ipilimumab plus nivolumab.